ATE519485T1 - Akute pharmakologische verstärkung einer psychotherapie mit d-cycloserine - Google Patents

Akute pharmakologische verstärkung einer psychotherapie mit d-cycloserine

Info

Publication number
ATE519485T1
ATE519485T1 AT02739111T AT02739111T ATE519485T1 AT E519485 T1 ATE519485 T1 AT E519485T1 AT 02739111 T AT02739111 T AT 02739111T AT 02739111 T AT02739111 T AT 02739111T AT E519485 T1 ATE519485 T1 AT E519485T1
Authority
AT
Austria
Prior art keywords
psychotherapy
methods
disorders
brain
those
Prior art date
Application number
AT02739111T
Other languages
English (en)
Inventor
Michael Davis
Kerry J Ressler
Original Assignee
Michael Davis
Kerry J Ressler
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Michael Davis, Kerry J Ressler filed Critical Michael Davis
Application granted granted Critical
Publication of ATE519485T1 publication Critical patent/ATE519485T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Psychiatry (AREA)
  • Emergency Medicine (AREA)
  • Psychology (AREA)
  • Anesthesiology (AREA)
  • Pain & Pain Management (AREA)
  • Addiction (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AT02739111T 2001-03-29 2002-03-28 Akute pharmakologische verstärkung einer psychotherapie mit d-cycloserine ATE519485T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US27986801P 2001-03-29 2001-03-29
US36399102P 2002-03-13 2002-03-13
PCT/US2002/009467 WO2002078629A2 (en) 2001-03-29 2002-03-28 Acute pharmacologic augmentation of psychotherapy with enhancers of learning or conditioning

Publications (1)

Publication Number Publication Date
ATE519485T1 true ATE519485T1 (de) 2011-08-15

Family

ID=26959924

Family Applications (1)

Application Number Title Priority Date Filing Date
AT02739111T ATE519485T1 (de) 2001-03-29 2002-03-28 Akute pharmakologische verstärkung einer psychotherapie mit d-cycloserine

Country Status (7)

Country Link
US (1) US7750030B2 (de)
EP (1) EP1383465B1 (de)
JP (1) JP2004530666A (de)
AT (1) ATE519485T1 (de)
AU (1) AU2002311784B2 (de)
CA (1) CA2442330A1 (de)
WO (1) WO2002078629A2 (de)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6541033B1 (en) 1998-06-30 2003-04-01 Amgen Inc. Thermosensitive biodegradable hydrogels for sustained delivery of leptin
US20050096396A1 (en) * 2002-03-28 2005-05-05 Emory University Acute pharmacologic augmentation of psychotherapy with enhancers of learning or conditioning
WO2005016319A2 (en) * 2003-08-06 2005-02-24 Emory University Acute pharmacologic augmentation of psychotherapy with enhancers of learning or conditioning
ATE519485T1 (de) 2001-03-29 2011-08-15 Michael Davis Akute pharmakologische verstärkung einer psychotherapie mit d-cycloserine
US20070105960A1 (en) * 2003-08-27 2007-05-10 Eli Lilly And Company Treatment of learning disabilities and motor skills disorder with norepinephrine reuptake inhibitors
KR20070007276A (ko) * 2003-12-29 2007-01-15 제이슨 맥데빗 재발성 의학적 증상을 치료하기 위한 조성물 및 방법
EP1779867A4 (de) * 2004-07-01 2009-12-02 Eisai R&D Man Co Ltd Mittel zur förderung der nervenreveneration
US20060084659A1 (en) * 2004-10-19 2006-04-20 Michael Davis Augmentation of psychotherapy with cannabinoid reuptake inhibitors
EP2275096A3 (de) * 2005-08-26 2011-07-13 Braincells, Inc. Neurogenese durch modulation des Muscarinrezeptors
EP2258357A3 (de) * 2005-08-26 2011-04-06 Braincells, Inc. Neurogenese mit Acetylcholinesterasehemmer
TW200820963A (en) * 2006-07-28 2008-05-16 Xenoport Inc Acyloxyalkyl carbamate prodrugs of α-amino acids, methods of synthesis and use
WO2008098245A2 (en) * 2007-02-09 2008-08-14 University Of Georgia Reseach Foundation, Inc. Nmda receptor modulation and treatments for addictive behavior
US20100113453A1 (en) * 2007-04-10 2010-05-06 Mcdevitt Jason P Sublingual Formulations of D-Cycloserine and Methods of Using Same
US20080280276A1 (en) * 2007-05-09 2008-11-13 Oregon Health & Science University And Oregon Research Institute Virtual reality tools and techniques for measuring cognitive ability and cognitive impairment
US9560967B2 (en) 2008-04-24 2017-02-07 The Invention Science Fund I Llc Systems and apparatus for measuring a bioactive agent effect
US9064036B2 (en) 2008-04-24 2015-06-23 The Invention Science Fund I, Llc Methods and systems for monitoring bioactive agent use
US9662391B2 (en) 2008-04-24 2017-05-30 The Invention Science Fund I Llc Side effect ameliorating combination therapeutic products and systems
US9649469B2 (en) 2008-04-24 2017-05-16 The Invention Science Fund I Llc Methods and systems for presenting a combination treatment
US9282927B2 (en) 2008-04-24 2016-03-15 Invention Science Fund I, Llc Methods and systems for modifying bioactive agent use
US9449150B2 (en) 2008-04-24 2016-09-20 The Invention Science Fund I, Llc Combination treatment selection methods and systems
US9239906B2 (en) 2008-04-24 2016-01-19 The Invention Science Fund I, Llc Combination treatment selection methods and systems
US9026369B2 (en) 2008-04-24 2015-05-05 The Invention Science Fund I, Llc Methods and systems for presenting a combination treatment
US20100204291A1 (en) * 2009-02-12 2010-08-12 Mcdevitt Jason P Method for Facilitating Extinction Training Using D-Cycloserine
EP3369730B1 (de) 2012-11-05 2020-08-05 Emory University 7,8-dihydoxyflavon und 7,8-substituierte flavonderivate, zusammensetzungen und zugehörige verfahren
US9877951B2 (en) 2015-02-12 2018-01-30 College Of William And Mary Method for treating dementia
EP4185290A4 (de) * 2020-07-24 2024-07-03 Cognifisense, Inc. Kombinatorische therapeutische systeme und verfahren mit systemischen, zentral und peripher wirkenden analgetika
WO2024091523A1 (en) * 2022-10-24 2024-05-02 2A Biosciences, Inc. Conformationally restricted phenethylamine analogs

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR7131M (de) * 1968-01-31 1969-07-21
US4727062A (en) 1986-03-17 1988-02-23 Merck & Co., Inc. 3-Halovinylglycine antibacterial agents
US5468763A (en) 1987-12-01 1995-11-21 G. D. Searle & Co. Use of a glycine B partial agonist for memory and learning enhancement or treatment of a cognitive disorder
US5087633A (en) 1987-12-01 1992-02-11 G. D. Searle & Co. Use of a glycine B partial agonist for memory and learning enhancement or treatment of a cognitive disorder
US4904681A (en) 1987-12-01 1990-02-27 G. D. Searle & Co. D-cycloserine and its prodrugs as cognitive enhancers
US5187171A (en) 1989-01-09 1993-02-16 G. D. Searle & Co. Use of a glycine b partial agonist as an antipsychotic
US5061721A (en) * 1989-03-15 1991-10-29 G. D. Searle & Co. Composition containing d-cycloserine and d-alanine for memory and learning enhancement or treatment of a cognitive or psychotic disorder
JPH03236315A (ja) 1989-12-05 1991-10-22 Nippon Oil & Fats Co Ltd 抗精神病薬
US5260324A (en) 1990-02-06 1993-11-09 G. D. Searle & Company Composition containing D-cycloserine and D-alanine for memory and learning enhancement or treatment of a cognitive or psychotic disorder
US5086072A (en) 1990-06-18 1992-02-04 The United States Of America As Represented By The Department Of Health And Human Services Treatment of mood disorders with functional antagonists of the glycine/nmda receptor complex
US5194371A (en) 1991-07-31 1993-03-16 Bristol-Myers Squibb Company Production of pradimicin antibiotics
US5854217A (en) * 1992-09-28 1998-12-29 Bearsden Bio, Inc. Allosteric modulators of the NMDA receptor and their use in the treatment of CNS disorders and enhancement of CNS function
US5428069A (en) 1993-01-11 1995-06-27 The United States Of America As Represented By The Department Of Health & Human Services Treating cognition with, aminocyclopropanecarboxylic derivatives
US5523323A (en) * 1993-09-14 1996-06-04 Maccecchini; Maria-Luisa Use of partial agonists of the NMDA receptor to reduce opiate induced tolerance and dependence
AU4019395A (en) 1994-11-23 1996-06-17 G.D. Searle & Co. Use of amino-isoxazolidone compounds for improvement of implicit memory
AU4128896A (en) 1994-11-23 1996-06-17 G.D. Searle & Co. Use of amino-isoxazolidone compounds for treatment of memory impairment following traumatic brain injury
US6271015B1 (en) 1995-06-12 2001-08-07 The Scripps Research Institute Fatty-acid amide hydrolase
US6355681B2 (en) 1995-12-07 2002-03-12 Glytech, Inc. Glycine substitutes and precursors for treating a psychosis
UA57107C2 (uk) 1997-09-23 2003-06-16 Елі Ліллі Енд Компані Спосіб лікування розладу поведінки
UA56257C2 (uk) 1997-09-23 2003-05-15 Елі Ліллі Енд Компані Спосіб лікування неадекватної визивної поведінки
US6391922B1 (en) * 1998-01-13 2002-05-21 Synchroneuron, Llc Treatment of posttraumatic stress disorder, obsessive-compulsive disorder and related neuropsychiatric disorders
AU765603C (en) 1998-04-14 2004-08-05 General Hospital Corporation, The Methods for treating neuropsychiatric disorders
EP1084704B1 (de) 1998-06-10 2006-03-29 Meiji Seika Kaisha Ltd. Arzneimittel für hinterstrangataxie und zusammensetzung zur behandlung von hinterstrangataxie
US6943166B1 (en) 1999-04-30 2005-09-13 Lilly Icos Llc. Compositions comprising phosphodiesterase inhabitors for the treatment of sexual disfunction
US6333357B1 (en) 1999-11-05 2001-12-25 Be Able, Llc Behavior chemotherapy
US6462054B1 (en) 2000-03-27 2002-10-08 The Scripps Research Institute Inhibitors of fatty acid amide hydrolase
AU2002248909A1 (en) 2000-11-15 2002-05-27 Minerva Biotechnologies Corporation Use of suramine, l-histidine, quisqualic acid or d-cycloserine for angiogenesis inhibition
WO2005016319A2 (en) 2003-08-06 2005-02-24 Emory University Acute pharmacologic augmentation of psychotherapy with enhancers of learning or conditioning
US20050096396A1 (en) 2002-03-28 2005-05-05 Emory University Acute pharmacologic augmentation of psychotherapy with enhancers of learning or conditioning
ATE519485T1 (de) 2001-03-29 2011-08-15 Michael Davis Akute pharmakologische verstärkung einer psychotherapie mit d-cycloserine
MXPA03009850A (es) 2001-04-27 2004-02-12 Bristol Myers Squibb Co Inhibidores de bisarilimidazolil de hidrolasa de amida del acido graso.
PL373970A1 (en) 2002-02-08 2005-09-19 Bristol-Myers Squibb Company (oxime)carbamoyl fatty acid amide hydrolase inhibitors
NZ570989A (en) 2002-05-16 2010-01-29 Sepracor Inc Amines that inhibit a mammalian anandamide transporter, and methods of use thereof
EP1558591B1 (de) 2002-10-07 2014-05-07 The Regents of The University of California Modulation von angstzuständen durch blockade der anandamidhydrolyse
IL154318A (en) 2003-02-06 2010-05-31 Sarah Herzog Memorial Hospital Pharmaceutical compositions for the treatment of movement disorders
KR20070007276A (ko) 2003-12-29 2007-01-15 제이슨 맥데빗 재발성 의학적 증상을 치료하기 위한 조성물 및 방법
US20060084659A1 (en) 2004-10-19 2006-04-20 Michael Davis Augmentation of psychotherapy with cannabinoid reuptake inhibitors

Also Published As

Publication number Publication date
EP1383465A2 (de) 2004-01-28
JP2004530666A (ja) 2004-10-07
US7750030B2 (en) 2010-07-06
WO2002078629A3 (en) 2002-11-28
EP1383465A4 (de) 2009-04-15
AU2002311784B8 (en) 2002-10-15
EP1383465B1 (de) 2011-08-10
AU2002311784B2 (en) 2007-11-22
US20040208923A1 (en) 2004-10-21
WO2002078629A2 (en) 2002-10-10
CA2442330A1 (en) 2002-10-10

Similar Documents

Publication Publication Date Title
WO2002078629A3 (en) Acute pharmacologic augmentation of psychotherapy with enhancers of learning or conditioning
AU6110301A (en) Diagnostics and therapeutics for macular degeneration-related disorders
DK1355889T3 (da) Substituerede triazoldiaminderivater som kinaseinhibitorer
MXPA04004714A (es) Derivados de aril 1,4-pirazina sustituidos.
MY130489A (en) Substituted aryl 1, 4-pyrazine derivatives
WO2003014873A3 (en) Interactive program guide configuration system
AR039832A1 (es) Catalizadores de reforma de bismuto y fosforo, su metodo de elaboracion y el proceso de reforma de nafta
ECSP045098A (es) Procedimientos para tratar enfermedades neovasculares oculares
NO20010539D0 (no) Behandling av avhengighet og avhengighet-relatert oppförsel
WO2001071609A8 (en) System and method for advertising with an internet voice portal
DE602006017123D1 (de) Einrichtungen und verfahren zum garantieren von dienstanforderungen auf benutzergerätebasis in einen träger
SG159393A1 (en) System and method for building and execution of platform-neutral generic servicesæ client applications
DE69525369D1 (de) Kontinuierliches polymerisationverfahren von polyamiden
ATE405888T1 (de) Verfahren, vorrichtung und system für einen mobil-web-client
TW200633458A (en) User authentication by linking randomly-generated authentication secret with personalized secret
BR9703302A (pt) Aparelho e método para a geração e uso de ìons férricos
NO20033821D0 (no) Anvendelse av GABA A inverse agonister i kombinasjon med nikotinreseptordelagonister, östrogen, selektive östrogenmodulatorer, ellervitamin E for behandling av kognitive forstyrrelser
BR9916544A (pt) Processo para tratamento de neoplasia em um indivìduo que necessita de tal tratamento, e, combinação
DE60207289D1 (de) Verfahren und vorrichtung zur symmetrischen schlüsselerzeugung in einer persönlichen sicherheitsvorrichtung mit begrenzten vertrauensbeziehungen
DE69737955D1 (de) Gerät zur reduzierung der spannung der herzwand
ATE396571T1 (de) Verfahren und vorrichtung für einen computerfirewall
ATE533101T1 (de) Bedienvorrichtung
WO2002073196A3 (en) Individualization of therapy with antipsychotics
DK0732965T1 (da) Anordning ved el-ledningspoler
CY1110202T1 (el) Νεοι συνδυασμοι ενος αντι εμετικου παραγοντα και ενος αναστολεα της εγκεφαλινασης

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties